Back to results
US 2023/0265381 A1Published application
Novel cell line
OwnerDavid Johannes Francois DU PLESSIS, Anggakusumainventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to insect cell lines for the production of parvoviral gene therapy vectors. In particular the invention relates to stable insect cell lines with expression constructs for viral replicase proteins integrated into their genomes, which cell lines allow for high-yield, robust, and scalable production of heterologous parvoviral-related proteins and vectors.
Claims20
An insect cell comprising, integrated into the genome of the cell:
- (i) a first promoter operably linked to a nucleotide sequence encoding an mRNA, translation of which in the cell produces at least one of parvoviral Rep 78 and 68 proteins;
- (ii) a second promoter operably linked to a nucleotide sequence encoding an mRNA, translation of which in the cell produces at least one of parvoviral Rep 52 and 40 proteins;
- and
- (iii) at least one enhancer element that is operably linked to the first and second promoters, wherein the at least one enhancer element is dependent on a transcriptional transregulator, wherein introduction of the transcriptional transregulator into the cell induces transcription from the first and second promoters.
1 more element
Dependencies are inferred from the claim text.